Verapamil and Catamenial Epilepsy
Information source: University Health Network, Toronto
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Catamenial Epilepsy
Intervention: verapamil hyrochloride (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: University Health Network, Toronto Official(s) and/or principal investigator(s):
Danielle Andrade, MD, Principal Investigator, Affiliation: College of Physicians and Surgeons of Ontario
Overall contact:
Nina Politzer, BScN, Phone: 416 603-5800, Ext: 2446, Email: nina.politzer@uhn.on.ca
Summary
One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related
to the over expression of multidrug resistance proteins (MDR). Progesterone is a known
inhibitor of MDRs and the low level of this hormone during the menstrual cycle may
exacerbate seizures, perhaps explaining catamenial epilepsy; i. e. seizures occurring during
the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by
inhibiting MDRs and thus may help patients with refractory seizures. If the study shows
improved seizure control, the results will help establish the role of MDRs in refractory
epilepsy.
Clinical Details
Official title: Study of Verapamil in Refractory Catamenial Epilepsy
Study design: Treatment, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study
Primary outcome: the percent reduction in seizure frequency
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- females
- at least 2 seizures per month
- more than 50% of the seizures occur 7 days before or 7 days after the onset of menses
- patient of the Toronto Western Hospital Epilepsy Clinic
Exclusion Criteria:
- cardiovascular history
Locations and Contacts
Nina Politzer, BScN, Phone: 416 603-5800, Ext: 2446, Email: nina.politzer@uhn.on.ca
Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada
Additional Information
Starting date: February 2008
Ending date: December 2010
Last updated: November 14, 2007
|
